BioMedNewsBreaks – Intec Pharma Ltd. (NASDAQ: NTEC) Featured by M-Vest
Feb 5, 2021
Intec Pharma (NASDAQ: NTEC), a clinical-stage biopharmaceutical company, was recently highlighted as a featured company by M-Vest. The business description reads, “Intec’s strategy is to leverage its proprietary delivery technology to improve the properties of known/approved compounds. Intec also plans to work in collaboration with biotechnology and pharmaceutical companies to develop novel delivery systems for their proprietary drugs, including existing compounds undergoing lifecycle management.”
For more details, visit https://ibn.fm/WUpyI
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill(R) platform technology. The company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The company’s product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, or AP-CD/LD, which is in late-stage Phase 3 development for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in cannabis sativa, cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”) for various pain indications. In addition, the company has a research collaboration with Merck & Co. For more information, visit www.IntecPharma.com.
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
[email protected]
BioMedWire is part of the InvestorBrandNetwork
More News
Sir Jim Ratcliffe suspends production at key UK plants blaming high gas prices
Ineos said natural gas in the UK is twelve times more expensive than in the US.
How Unions Are Confronting A.I. Threats in the Workplace
The machinists union shows how workers are negotiating for a say in the ways artificial intelligence is used in their workplaces.
What Is the White House Press Pool, and Why Did It Suspend TV Coverage of Trump?
By barring CNN, the White House has thrown a staple of TV news coverage into disarray.
CNN’s Future Will Include an Editorial Oversight Board
The looming ownership of the network by David Ellison has caused anxiety in its newsroom for months.
What’s Next for Paramount
Hollywood watchers believe the studio prevailed over states seeking to block its deal for Warner Bros. Discovery. It’s now free to reshape the media industry.
New EU industry rules would damage UK, warns Burnham
The prime minister says he will raise his concerns when he meets the European Commission President later.
China’s Continued Control of Rare Earths Looms Over Trump-Xi Meeting
Manufacturers are struggling with constrained supplies as U.S. and Chinese officials negotiate over export restrictions with consequences for global industry.
Paramount settles lawsuit with US states, clearing way for $110bn merger with Warner Bros
The deal includes an agreement to produce 30 films a year, or Paramount will be forced to sell off parts of its company.
Are vet bills about to get cheaper?
Written prescription fees from vets will be capped at £21 as part of a raft of changes that practices will be legally required to bring in over the coming months.
Spain battles climate change on several fronts
A summer of wildfires and heatwaves underlines the threats to the country's economy.
Paramount’s Warner Bros. Takeover Makes David Ellison a Hollywood Mega-Mogul
With Paramount and Warner Bros. under his control, Mr. Ellison will be “the Hollywood equivalent of Superman, Caesar and Midas combined.” But challenges remain.
What’s Behind Bessent’s Boasts About the U.S. Bond Market
By one measure, U.S. government bond markets have posted negative returns, but markets in others countries have experienced steeper losses.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.